Last reviewed · How we verify
Moderate to severe psoriatic arthritis and axial spondyloarthritis
Approved treatments
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe psoriatic arthritis and axial spondyloarthritis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe psoriatic arthritis and axial spondyloarthritis treatment landscape brief
- Moderate to severe psoriatic arthritis and axial spondyloarthritis treatment updates RSS
Frequently asked questions about Moderate to severe psoriatic arthritis and axial spondyloarthritis
What drugs treat Moderate to severe psoriatic arthritis and axial spondyloarthritis?
Tracked treatments include Chronic- PF-06480605 50 mg SC Q4W.
What is the treatment for Moderate to severe psoriatic arthritis and axial spondyloarthritis?
Standard treatment for Moderate to severe psoriatic arthritis and axial spondyloarthritis includes Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe psoriatic arthritis and axial spondyloarthritis patent cliff · Moderate to severe psoriatic arthritis and axial spondyloarthritis CI report
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing